395 related articles for article (PubMed ID: 29523175)
1. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan.
Onland W; Merkus MP; Nuytemans DH; Jansen-van der Weide MC; Holman R; van Kaam AH;
Trials; 2018 Mar; 19(1):178. PubMed ID: 29523175
[TBL] [Abstract][Full Text] [Related]
2. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial.
Onland W; Cools F; Kroon A; Rademaker K; Merkus MP; Dijk PH; van Straaten HL; Te Pas AB; Mohns T; Bruneel E; van Heijst AF; Kramer BW; Debeer A; Zonnenberg I; Marechal Y; Blom H; Plaskie K; Offringa M; van Kaam AH;
JAMA; 2019 Jan; 321(4):354-363. PubMed ID: 30694322
[TBL] [Abstract][Full Text] [Related]
3. Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial.
Onland W; Offringa M; Cools F; De Jaegere AP; Rademaker K; Blom H; Cavatorta E; Debeer A; Dijk PH; van Heijst AF; Kramer BW; Kroon AA; Mohns T; van Straaten HL; te Pas AB; Theyskens C; van Weissenbruch MM; van Kaam AH
BMC Pediatr; 2011 Nov; 11():102. PubMed ID: 22070744
[TBL] [Abstract][Full Text] [Related]
4. Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial.
He Y; Zhang Y; Gao S; Wang X; He N; Zhang D; Dong W; Wieg C; Lei X
Trials; 2020 Sep; 21(1):762. PubMed ID: 32883333
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis.
Morris IP; Goel N; Chakraborty M
Eur J Pediatr; 2019 Aug; 178(8):1171-1184. PubMed ID: 31144162
[TBL] [Abstract][Full Text] [Related]
6. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
Baud O; Maury L; Lebail F; Ramful D; El Moussawi F; Nicaise C; Zupan-Simunek V; Coursol A; Beuchée A; Bolot P; Andrini P; Mohamed D; Alberti C;
Lancet; 2016 Apr; 387(10030):1827-36. PubMed ID: 26916176
[TBL] [Abstract][Full Text] [Related]
7. Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.
Watterberg KL; Walsh MC; Li L; Chawla S; D'Angio CT; Goldberg RN; Hintz SR; Laughon MM; Yoder BA; Kennedy KA; McDavid GE; Backstrom-Lacy C; Das A; Crawford MM; Keszler M; Sokol GM; Poindexter BB; Ambalavanan N; Hibbs AM; Truog WE; Schmidt B; Wyckoff MH; Khan AM; Garg M; Chess PR; Reynolds AM; Moallem M; Bell EF; Meyer LR; Patel RM; Van Meurs KP; Cotten CM; McGowan EC; Hines AC; Merhar S; Peralta-Carcelen M; Wilson-Costello DE; Kilbride HW; DeMauro SB; Heyne RJ; Mosquera RA; Natarajan G; Purdy IB; Lowe JR; Maitre NL; Harmon HM; Hogden LA; Adams-Chapman I; Winter S; Malcolm WF; Higgins RD;
N Engl J Med; 2022 Mar; 386(12):1121-1131. PubMed ID: 35320643
[TBL] [Abstract][Full Text] [Related]
8. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review.
Doyle LW; Ehrenkranz RA; Halliday HL
Neonatology; 2010; 98(2):111-7. PubMed ID: 20150750
[TBL] [Abstract][Full Text] [Related]
9. The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants < 29 weeks' gestation.
Collins CT; Gibson RA; Makrides M; McPhee AJ; Sullivan TR; Davis PG; Thio M; Simmer K; Rajadurai VS;
BMC Pediatr; 2016 Jun; 16():72. PubMed ID: 27250120
[TBL] [Abstract][Full Text] [Related]
10. [The use of postnatal corticosteroid therapy in premature infants to prevent or treat bronchopulmonary dysplasia: current situation and recommendations].
Jarreau PH; Fayon M; Baud O; Autret-Leca E; Danan M; de Verdelhan A; Castot A
Arch Pediatr; 2010 Oct; 17(10):1480-7. PubMed ID: 20864322
[TBL] [Abstract][Full Text] [Related]
11. Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age.
Baud O; Trousson C; Biran V; Leroy E; Mohamed D; Alberti C;
JAMA; 2017 Apr; 317(13):1329-1337. PubMed ID: 28384828
[TBL] [Abstract][Full Text] [Related]
12. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: statistical analysis plan for the international, multicenter, randomized PLUSS trial.
Francis KL; McKinlay CJD; Kamlin COF; Cheong JLY; Dargaville PA; Dawson JA; Doyle LW; Jacobs SE; Davis PG; Donath SM; Manley BJ
Trials; 2023 Nov; 24(1):709. PubMed ID: 37932774
[TBL] [Abstract][Full Text] [Related]
13. Pentoxifylline for the prevention of bronchopulmonary dysplasia in preterm infants.
Schulzke SM; Kaempfen S; Patole SK
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010018. PubMed ID: 25418278
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial: A Secondary Analysis of a Randomized Clinical Trial.
Gentle SJ; Rysavy MA; Li L; Laughon MM; Patel RM; Jensen EA; Hintz S; Ambalavanan N; Carlo WA; Watterberg K;
JAMA Netw Open; 2023 May; 6(5):e2315315. PubMed ID: 37256621
[TBL] [Abstract][Full Text] [Related]
15. Effect of Systemic Hydrocortisone on Brain Abnormalities and Regional Brain Volumes in Ventilator-dependent Infants Born Preterm: Substudy of the SToP-BPD Study.
Halbmeijer NM; Onland W; Dudink J; Cools F; Debeer A; van Kaam AH; Benders MJNL; van der Aa NE
J Pediatr; 2024 Feb; 265():113807. PubMed ID: 37923196
[TBL] [Abstract][Full Text] [Related]
16. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
Bassler D
Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial.
Watterberg KL; Gerdes JS; Cole CH; Aucott SW; Thilo EH; Mammel MC; Couser RJ; Garland JS; Rozycki HJ; Leach CL; Backstrom C; Shaffer ML
Pediatrics; 2004 Dec; 114(6):1649-57. PubMed ID: 15574629
[TBL] [Abstract][Full Text] [Related]
18. [Glucocorticoide therapy in premature infants: French practices in 2006].
Autret-Leca E; Bauer S; Alberti C; Jonville-Béra AP; Aujard Y; Bensouda-Grimaldi L; Baud O
Arch Pediatr; 2009 Jul; 16(7):999-1004. PubMed ID: 19410441
[TBL] [Abstract][Full Text] [Related]
19. Early inhaled nitric oxide in preterm infants <34 weeks with evolving bronchopulmonary dysplasia.
Jiang Q; Gao X; Liu C; Chen D; Lin X; Xia S; Zhuang D; Yang C; Zhu W; Liu L; Chen C; Sun B
J Perinatol; 2016 Oct; 36(10):883-9. PubMed ID: 27442155
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic postnatal corticosteroids: Early hydrocortisone.
Baud O; Watterberg KL
Semin Fetal Neonatal Med; 2019 Jun; 24(3):202-206. PubMed ID: 31043325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
